Assessment of basal and stimulated C-peptide in patients with type 1 diabetes mellitus on the administration of tolerogenic dendritic cells

Tatsiana Mokhort; Volha Shyshko; Alena Mokhort; Andrei Hancharou; Natalia Antonevich; Yana Minich; Volha Lazovtseva; Alena Dashkevich; Elena Shishko

doi:10.1530/endoabs.99.EP20

EP20

Prev Next

Section Contents Cite

Endocrine Abstracts (2024) 99 EP20 | DOI: 10.1530/endoabs.99.EP20

ECE2024 Eposter Presentations Diabetes, Obesity, Metabolism and Nutrition (383 abstracts)

Assessment of basal and stimulated C-peptide in patients with type 1 diabetes mellitus on the administration of tolerogenic dendritic cells

Tatsiana Mokhort ¹ , Volha Shyshko ² , Alena Mokhort ³ , Andrei Hancharou ⁴ , Natalia Antonevich ⁴ , Yana Minich ⁴ , Volha Lazovtseva ¹ , Alena Dashkevich ⁵ & Elena Shishko ³

Views

Author affiliations

¹Belarusian State Medical University, Minsk, Belarus; ²Minsk City Clinical Endocrinological Center, Minsk, Belarus; ³Belarusian State Medical University, Endocrinology, Minsk, Belarus; ⁴The Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus; ⁵10th City Clinical Hospital, Minsk, Belarus

Introduction: Preserving of C-peptide secretion in type 1 diabetes mellitus (DM1) is an important goal in treatment, as it provides the possibility of optimal compensation. We initiated a study (ClinicalTrials.gov 26.01.2022, NCT05207995) to assess the potential effect of Tolerant Dendritic Cells (tolDC) on the newly diagnosed DM1.

Methods: Evaluation of stimulated C-peptide against the background of a standard breakfast (carbohydrate content of 50g) was carried out twice (before tol-DC therapy) (n=14) and 3 months after completion of therapy (n=9). The test was performed with fasting glycemia in the range of 3.8 - 9.0 mmol/l, short-acting insulin was not administered before breakfast. The test was carried out for 2 hours with the determination of the level of C-peptide at 0, 30, 60, 90 and 120 minutes. The levels of C-peptide after food stimulation were studied with the calculation of AUC (area under curve). All patients (n=16) had their basal C-peptide levels determined twice. Determination of the level of C-peptide is carried out by the method of chemiluminescent enzyme immunoassay on the analyzer Cobas E411 by Roche Diagnostics (Germany).

Results: The median (Me, Q1; Q3) basal C-peptide level before therapy was 0.74 (0.71; 0.77) ng/ml, which met the requirements for inclusion in the study. Data obtained 3 months after completion of the study indicate that C-peptide secretion remained at 0.87 (0.68, 1.06) ng/ml. The AUC value before administration of tolDC was 409±202.5 ng/ml×2 h. After therapy, AUC was 385.6±145.5 ng/ml×2 h; no significant differences with the AUC level before tolDC therapy were detected (P=0.18).

Conclusion: Our results indicate the potential effectiveness of the method for correcting carbohydrate metabolism in patients with type 1 diabetes using tolDC. Short-term use of Tolerogenic Dendritic Cells is accompanied by preservation of C-peptide secretion, which is a prognostically favorable factor in the course of DM1.